{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:06:15Z","timestamp":1792029975239,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s10741-019-09906-x","type":"journal-article","created":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T08:03:18Z","timestamp":1578038598000},"page":"101-109","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Effects of angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker use on cancer therapy-related cardiac dysfunction: a meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7269-242X","authenticated-orcid":false,"given":"Kuaifa","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuifang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,3]]},"reference":[{"issue":"1","key":"9906_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7\u201334. https:\/\/doi.org\/10.3322\/caac.21551","journal-title":"CA Cancer J Clin"},{"key":"9906_CR2","doi-asserted-by":"publisher","first-page":"117954681986644","DOI":"10.1177\/1179546819866445","volume":"13","author":"IE Perez","year":"2019","unstructured":"Perez IE, Taveras Alam S, Hernandez GA, Sancassani R (2019) Cancer therapy-related cardiac dysfunction: an overview for the clinician. Clin Med Insights Cardiol 13:1179546819866445. https:\/\/doi.org\/10.1177\/1179546819866445","journal-title":"Clin Med Insights Cardiol"},{"key":"9906_CR3","doi-asserted-by":"publisher","first-page":"175394471984343","DOI":"10.1177\/1753944719843435","volume":"13","author":"CP Shah","year":"2019","unstructured":"Shah CP, Moreb JS (2019) Cardiotoxicity due to targeted anticancer agents: a growing challenge. Ther Adv Cardiovasc Dis 13:1753944719843435. https:\/\/doi.org\/10.1177\/1753944719843435","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"12","key":"9906_CR4","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1136\/heartjnl-2017-312103","volume":"104","author":"PA Henriksen","year":"2018","unstructured":"Henriksen PA (2018) Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart 104(12):971\u2013977. https:\/\/doi.org\/10.1136\/heartjnl-2017-312103","journal-title":"Heart"},{"issue":"11","key":"9906_CR5","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97(11):2869\u20132879. https:\/\/doi.org\/10.1002\/cncr.11407","journal-title":"Cancer"},{"issue":"21","key":"9906_CR6","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1111\/bph.13643","volume":"174","author":"BT Nemeth","year":"2017","unstructured":"Nemeth BT, Varga ZV, Wu WJ, Pacher P (2017) Trastuzumab cardiotoxicity: from clinical trials to experimental studies. Br J Pharmacol 174(21):3727\u20133748. https:\/\/doi.org\/10.1111\/bph.13643","journal-title":"Br J Pharmacol"},{"key":"9906_CR7","doi-asserted-by":"publisher","unstructured":"Padegimas A, Clasen S, Ky B (2019) Cardioprotective strategies to prevent breast cancer therapy-induced cardiotoxicity. Trends Cardiovasc Med. https:\/\/doi.org\/10.1016\/j.tcm.2019.01.006","DOI":"10.1016\/j.tcm.2019.01.006"},{"issue":"Pt A","key":"9906_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.phrs.2017.05.020","volume":"125","author":"CM Ferrario","year":"2017","unstructured":"Ferrario CM, Mullick AE (2017) Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease. Pharmacol Res 125(Pt A):57\u201371. https:\/\/doi.org\/10.1016\/j.phrs.2017.05.020","journal-title":"Pharmacol Res"},{"issue":"2","key":"9906_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jacc.2012.10.011","volume":"61","author":"G Savarese","year":"2013","unstructured":"Savarese G, Costanzo P, Cleland JG, Vassallo E, Ruggiero D, Rosano G, Perrone-Filardi P (2013) A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol 61(2):131\u2013142. https:\/\/doi.org\/10.1016\/j.jacc.2012.10.011","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"9906_CR10","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1158\/1078-0432.CCR-18-0236","volume":"24","author":"M Pinter","year":"2018","unstructured":"Pinter M, Kwanten WJ, Jain RK (2018) Renin-angiotensin system inhibitors to mitigate cancer treatment-related adverse events. Clin Cancer Res 24(16):3803\u20133812. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0236","journal-title":"Clin Cancer Res"},{"issue":"5","key":"9906_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/CRD.0000000000000252","volume":"27","author":"JB Blanter","year":"2019","unstructured":"Blanter JB, Frishman WH (2019) The preventive role of angiotensin converting enzyme inhibitors\/angiotensin-II receptor blockers and beta-adrenergic blockers in anthracycline- and trastuzumab-induced cardiotoxicity. Cardiol Rev 27(5):256\u2013259. https:\/\/doi.org\/10.1097\/CRD.0000000000000252","journal-title":"Cardiol Rev"},{"issue":"23","key":"9906_CR12","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","volume":"114","author":"D Cardinale","year":"2006","unstructured":"Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, Martinelli G, Veglia F, Fiorentini C, Cipolla CM (2006) Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114(23):2474\u20132481. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.635144","journal-title":"Circulation"},{"issue":"3","key":"9906_CR13","doi-asserted-by":"publisher","first-page":"487 e481","DOI":"10.1016\/j.ahj.2010.05.037","volume":"160","author":"C Cadeddu","year":"2010","unstructured":"Cadeddu C, Piras A, Mantovani G, Deidda M, Dessi M, Madeddu C, Massa E, Mercuro G (2010) Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J 160(3):487 e481\u2013487 e487. https:\/\/doi.org\/10.1016\/j.ahj.2010.05.037","journal-title":"Am Heart J"},{"issue":"11","key":"9906_CR14","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/ajh.21840","volume":"85","author":"P Georgakopoulos","year":"2010","unstructured":"Georgakopoulos P, Roussou P, Matsakas E, Karavidas A, Anagnostopoulos N, Marinakis T, Galanopoulos A, Georgiakodis F, Zimeras S, Kyriakidis M, Ahimastos A (2010) Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. Am J Hematol 85(11):894\u2013896. https:\/\/doi.org\/10.1002\/ajh.21840","journal-title":"Am J Hematol"},{"issue":"8","key":"9906_CR15","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","volume":"2","author":"AH Boekhout","year":"2016","unstructured":"Boekhout AH, Gietema JA, Milojkovic Kerklaan B, van Werkhoven ED, Altena R, Honkoop A, Los M, Smit WM, Nieboer P, Smorenburg CH, Mandigers CM, van der Wouw AJ, Kessels L, van der Velden AW, Ottevanger PB, Smilde T, de Boer J, van Veldhuisen DJ, Kema IP, de Vries EG, Schellens JH (2016) Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial. JAMA Oncol 2(8):1030\u20131037. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1726","journal-title":"JAMA Oncol"},{"issue":"21","key":"9906_CR16","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","volume":"37","author":"G Gulati","year":"2016","unstructured":"Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, von Knobelsdorff-Brenkenhoff F, Bratland A, Storas TH, Hagve TA, Rosjo H, Steine K, Geisler J, Omland T (2016) Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 37(21):1671\u20131680. https:\/\/doi.org\/10.1093\/eurheartj\/ehw022","journal-title":"Eur Heart J"},{"issue":"2","key":"9906_CR17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s12012-016-9365-z","volume":"17","author":"G Janbabai","year":"2017","unstructured":"Janbabai G, Nabati M, Faghihinia M, Azizi S, Borhani S, Yazdani J (2017) Effect of enalapril on preventing anthracycline-induced cardiomyopathy. Cardiovasc Toxicol 17(2):130\u2013139. https:\/\/doi.org\/10.1007\/s12012-016-9365-z","journal-title":"Cardiovasc Toxicol"},{"issue":"8","key":"9906_CR18","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","volume":"35","author":"E Pituskin","year":"2017","unstructured":"Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, Pagano JJ, Chow K, Thompson RB, Vos LJ, Ghosh S, Oudit GY, Ezekowitz JA, Paterson DI (2017) Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol 35(8):870\u2013877. https:\/\/doi.org\/10.1200\/JCO.2016.68.7830","journal-title":"J Clin Oncol"},{"issue":"11","key":"9906_CR19","doi-asserted-by":"publisher","first-page":"e27308","DOI":"10.1002\/pbc.27308","volume":"65","author":"V Gupta","year":"2018","unstructured":"Gupta V, Kumar Singh S, Agrawal V, Bali Singh T (2018) Role of ACE inhibitors in anthracycline-induced cardiotoxicity: a randomized, double-blind, placebo-controlled trial. Pediatr Blood Cancer 65(11):e27308. https:\/\/doi.org\/10.1002\/pbc.27308","journal-title":"Pediatr Blood Cancer"},{"issue":"22","key":"9906_CR20","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","volume":"73","author":"M Guglin","year":"2019","unstructured":"Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, McCaskill-Stevens W, Munster PN (2019) Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. J Am Coll Cardiol 73(22):2859\u20132868. https:\/\/doi.org\/10.1016\/j.jacc.2019.03.495","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"9906_CR21","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1016\/j.ejca.2013.04.030","volume":"49","author":"K Kalam","year":"2013","unstructured":"Kalam K, Marwick TH (2013) Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer 49(13):2900\u20132909. https:\/\/doi.org\/10.1016\/j.ejca.2013.04.030","journal-title":"Eur J Cancer"},{"issue":"1081","key":"9906_CR22","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1136\/postgradmedj-2015-133535","volume":"91","author":"S Yun","year":"2015","unstructured":"Yun S, Vincelette ND, Abraham I (2015) Cardioprotective role of beta-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis. Postgrad Med J 91(1081):627\u2013633. https:\/\/doi.org\/10.1136\/postgradmedj-2015-133535","journal-title":"Postgrad Med J"},{"key":"9906_CR23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.breast.2017.10.010","volume":"37","author":"DM Gujral","year":"2018","unstructured":"Gujral DM, Lloyd G, Bhattacharyya S (2018) Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy +\/\u2212 trastuzumab. Breast 37:64\u201371. https:\/\/doi.org\/10.1016\/j.breast.2017.10.010","journal-title":"Breast"},{"key":"9906_CR24","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535. https:\/\/doi.org\/10.1136\/bmj.b2535","journal-title":"BMJ"},{"key":"9906_CR25","unstructured":"Higgins J, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration www.cochranehandbook.org"},{"issue":"7414","key":"9906_CR26","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"issue":"11","key":"9906_CR27","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539\u20131558. https:\/\/doi.org\/10.1002\/sim.1186","journal-title":"Stat Med"},{"issue":"7109","key":"9906_CR28","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629\u2013634","journal-title":"BMJ"},{"issue":"1","key":"9906_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/eurheartj\/ehi555","volume":"27","author":"SJ Pocock","year":"2006","unstructured":"Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJ, Swedberg KB, Ostergren J, Michelson EL, Pieper KS, Granger CB (2006) Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 27(1):65\u201375. https:\/\/doi.org\/10.1093\/eurheartj\/ehi555","journal-title":"Eur Heart J"},{"issue":"5","key":"9906_CR30","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s40256-016-0173-4","volume":"16","author":"S Taddei","year":"2016","unstructured":"Taddei S, Bortolotto L (2016) Unraveling the pivotal role of bradykinin in ACE inhibitor activity. Am J Cardiovasc Drugs 16(5):309\u2013321. https:\/\/doi.org\/10.1007\/s40256-016-0173-4","journal-title":"Am J Cardiovasc Drugs"},{"key":"9906_CR31","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ejphar.2015.10.029","volume":"768","author":"R Sharma","year":"2015","unstructured":"Sharma R, Randhawa PK, Singh N, Jaggi AS (2015) Bradykinin in ischemic conditioning-induced tissue protection: evidences and possible mechanisms. Eur J Pharmacol 768:58\u201370. https:\/\/doi.org\/10.1016\/j.ejphar.2015.10.029","journal-title":"Eur J Pharmacol"},{"key":"9906_CR32","doi-asserted-by":"publisher","unstructured":"Marinello J, Delcuratolo M, Capranico G (2018) Anthracyclines as topoisomerase II poisons: from early studies to new perspectives. Int J Mol Sci 19(11). https:\/\/doi.org\/10.3390\/ijms19113480","DOI":"10.3390\/ijms19113480"},{"issue":"1","key":"9906_CR33","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/s1734-1140(09)70018-0","volume":"61","author":"T Simunek","year":"2009","unstructured":"Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R, Gersl V (2009) Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 61(1):154\u2013171. https:\/\/doi.org\/10.1016\/s1734-1140(09)70018-0","journal-title":"Pharmacol Rep"},{"key":"9906_CR34","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.freeradbiomed.2013.09.001","volume":"65","author":"TS Koskenkorva-Frank","year":"2013","unstructured":"Koskenkorva-Frank TS, Weiss G, Koppenol WH, Burckhardt S (2013) The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: insights into the potential of various iron therapies to induce oxidative and nitrosative stress. Free Radic Biol Med 65:1174\u20131194. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2013.09.001","journal-title":"Free Radic Biol Med"},{"issue":"Suppl 1","key":"9906_CR35","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1002\/ptr.811","volume":"16","author":"J Psotova","year":"2002","unstructured":"Psotova J, Chlopcikova S, Grambal F, Simanek V, Ulrichova J (2002) Influence of silymarin and its flavonolignans on doxorubicin-iron induced lipid peroxidation in rat heart microsomes and mitochondria in comparison with quercetin. Phytother Res 16(Suppl 1):S63\u2013S67. https:\/\/doi.org\/10.1002\/ptr.811","journal-title":"Phytother Res"},{"issue":"2","key":"9906_CR36","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/cvr\/cvx162","volume":"114","author":"R Hullin","year":"2018","unstructured":"Hullin R, Metrich M, Sarre A, Basquin D, Maillard M, Regamey J, Martin D (2018) Diverging effects of enalapril or eplerenone in primary prevention against doxorubicin-induced cardiotoxicity. Cardiovasc Res 114(2):272\u2013281. https:\/\/doi.org\/10.1093\/cvr\/cvx162","journal-title":"Cardiovasc Res"},{"issue":"2","key":"9906_CR37","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jtcvs.2010.07.097","volume":"142","author":"A Hiona","year":"2011","unstructured":"Hiona A, Lee AS, Nagendran J, Xie X, Connolly AJ, Robbins RC, Wu JC (2011) Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function. J Thorac Cardiovasc Surg 142(2):396\u2013403 e393. https:\/\/doi.org\/10.1016\/j.jtcvs.2010.07.097","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"1","key":"9906_CR38","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/jcp.25905","volume":"233","author":"CY Huang","year":"2018","unstructured":"Huang CY, Chen JY, Kuo CH, Pai PY, Ho TJ, Chen TS, Tsai FJ, Padma VV, Kuo WW (2018) Mitochondrial ROS-induced ERK1\/2 activation and HSF2-mediated AT1 R upregulation are required for doxorubicin-induced cardiotoxicity. J Cell Physiol 233(1):463\u2013475. https:\/\/doi.org\/10.1002\/jcp.25905","journal-title":"J Cell Physiol"},{"issue":"Suppl 35","key":"9906_CR39","doi-asserted-by":"publisher","first-page":"S4323","DOI":"10.21037\/jtd.2018.10.07","volume":"10","author":"M Delgobo","year":"2018","unstructured":"Delgobo M, Frantz S (2018) Heart failure in cancer: role of checkpoint inhibitors. J Thorac Dis 10(Suppl 35):S4323\u2013S4334. https:\/\/doi.org\/10.21037\/jtd.2018.10.07","journal-title":"J Thorac Dis"},{"key":"9906_CR40","doi-asserted-by":"publisher","unstructured":"Konala VM, Adapa S, Aronow WS (2019) Immune checkpoint inhibitors-related cardiotoxicity. Am J Ther. https:\/\/doi.org\/10.1097\/MJT.0000000000000988","DOI":"10.1097\/MJT.0000000000000988"},{"issue":"6","key":"9906_CR41","first-page":"1375","volume":"21","author":"XY Li","year":"2017","unstructured":"Li XY, Sun JF, Hu SQ (2017) The renin-angiotensin system blockers as adjunctive therapy for cancer: a meta-analysis of survival outcome. Eur Rev Med Pharmacol Sci 21(6):1375\u20131383","journal-title":"Eur Rev Med Pharmacol Sci"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-019-09906-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10741-019-09906-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-019-09906-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:34:39Z","timestamp":1609547679000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10741-019-09906-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,3]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["9906"],"URL":"https:\/\/doi.org\/10.1007\/s10741-019-09906-x","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,3]]},"assertion":[{"value":"3 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}